###### Strengths and limitations of this study

-   This large review was conducted according to best practices and includes the highest quality current evidence about the effects of zinc supplementation.

-   We investigated several outcomes and made multiple comparisons to explore the most important main effects and interactions.

-   The analyses in this review could not identify the best way to deliver zinc supplements to children in need.

Introduction {#s1}
============

Regular dietary zinc intake is required because zinc cannot be produced or stored.[@R1] [@R2] In 2011, 116 000 deaths in children under 5 years were attributable to zinc deficiency (1.7% of mortalities in this group).[@R3]

Previous reviews have reached disparate conclusions about the benefits of zinc supplementation for young children,[@R4] and most have not examined evidence for children over 5 years of age. Zinc deficiency is prevalent in areas with other micronutrient deficiencies. Concerns about the administration of zinc with iron have been an obstacle to widespread delivery.[@R13] Understanding the effects of preventive zinc supplementation alone and with iron is crucially important to the future of global health policy.

To evaluate the effects of zinc with or without iron on illness and mortality, as well as growth, we analysed direct comparisons (ie, zinc plus iron vs zinc alone) as well as subgroups within an overall analysis.

Methods {#s2}
=======

Selection criteria and search strategy {#s2a}
--------------------------------------

Following a published protocol,[@R14] we conducted a systematic review of randomised clinical trials of orally administered zinc compared with placebo and non-zinc cointerventions received by both groups (eg, vitamin A). We also compared zinc with and without iron cosupplementation. Participants were 6 months to 12 years of age. We excluded studies of food fortification and children who were acutely ill.

We searched the African Index Medicus, CENTRAL, Conference Proceedings Citation Index, EMBASE, Global Health, ICTRP, IndMED, LILACS, MEDLINE, metaRegister of Controlled Trials, ProQuest Dissertations & Theses Database and WHOLIS in December 2012 and January 2013 (see online supplementary appendix 1). Reference lists from previous reviews and from included studies were examined, and trial authors were contacted for unpublished data. Two authors independently reviewed citations and extracted data, including participant demographics, details of the intervention, outcomes and risk of bias.[@R15]

Data synthesis {#s2b}
--------------

Relative risks and 95% CIs were calculated using Mantel-Haenszel methods. Standardised mean differences (SMDs) and 95% CIs were calculated for continuous measures using Hedges g and combined using inverse variance methods. When studies reported data in multiple formats, we calculated the SMD and its SE in Comprehensive Meta-Analysis (CMA) V.2 before entering data in Review Manager (RevMan) V.5.2. For incidence data, we combined risk ratios (RR) (events per child) and rate ratios (events per child year) because trials were relatively short and we did not anticipate interactions between the intervention and time at risk. For cluster-randomised trials, we used effects controlling for clustering, or we used a intracluster correlation coefficient to estimate robust SEs.[@R15] We used fixed-effect methods for all meta-analyses. Effects favour intervention when the relative risk is reduced (RR\<1) or the standardised difference is positive (SMD\>0).

When 10 or more studies reported an outcome, we conducted subgroup analyses to explore the effects of iron cosupplementation, national income (low-income countries compared with others), stunting, age (6--12, more than 12 months), dose (0--5, 5--10 mg, etc), duration (0--6, 6--12, more than 12 months) and formulation.

Quality of the evidence {#s2c}
-----------------------

Quality of the evidence was judged independently using GRADE.[@R16] The GRADE system rates evidence from each analysis (ie, pooled data where possible) as 'high', 'moderate', 'low' or 'very low'. A 'high' rating suggests that evidence is unlikely to be affected by further studies; a 'low' rating suggests that further research is required to confirm the direction and magnitude of the true effect. Ratings for meta-analyses of randomised controlled trials start at 'high' and may be downgraded for threats to internal validity (ie, within-study bias), inconsistency (ie, heterogeneity in results across studies), indirectness (eg, measures are proxies for the true outcome of interest), imprecision (eg, few participants, wide CIs) and reporting bias (ie, publication bias and selective outcome reporting). Because GRADE considers several domains in addition to internal validity, confidence in overall effects may be 'low' or 'very low' even when all studies are conducted rigorously. The following sections include significant and non-significant statistical results, and GRADE ratings in the text and tables provide further information about our confidence in these estimates.

Results {#s3}
=======

Results of the search {#s3a}
---------------------

From 6384 records, 80 studies were included ([figure 1](#BMJOPEN2013004647F1){ref-type="fig"}). Seventy-five studies were published in English, two each in Spanish and Portuguese and one in Chinese. Reasons for excluding 27 studies were enumerated (see online supplementary appendix 2); additionally, 11 ongoing studies were identified, and 5 studies could not be obtained. Seven included studies did not contribute to any meta-analysis because they did not report sufficient data (see online supplementary appendix 3).

![PRISMA flow chart.](bmjopen2013004647f01){#BMJOPEN2013004647F1}

Study characteristics {#s3b}
---------------------

Included studies assigned 205 923 eligible participants (see online supplementary appendix 4). Twenty trials used factorial designs; there were 100 independent comparisons isolating zinc, and cointerventions were provided to both groups in 51 comparisons. There were eight independent comparisons of iron with zinc versus zinc alone including 1898 eligible participants. Sample sizes ranged from 21 to 72 438 eligible participants (median=200). Nine studies were cluster-randomised, including two randomising households. Three studies included 88% of participants.[@R17] Forty-six studies reported the mean baseline plasma or serum zinc concentration of their participants; the median of these mean concentrations was 72.5 μg/dL.

Thirty-two countries are represented; most studies were conducted in low-income or middle-income countries: 37 in Asia, 26 in Latin America and the Caribbean and 10 in sub-Saharan Africa. The median of mean age at baseline was 28 months, and 22 studies included children over 5 years of age. Stunted and non-stunted children were included in 42 studies; 5 included only stunted children, 5 included only non-stunted children and 28 did not specify if participants were stunted.

Studies provided zinc for less than 6 (30), 6--12 (33) and 12 months or more (16). Of those reporting frequency of zinc supplementation, 48 provided zinc daily and 11 provided zinc weekly. Where reported, daily dose was 0--5 (5), 5--10 (19), 10--15 (30), 15--20 (8) and 20 mg or more (12). Studies reporting the chemical compound of their zinc supplements provided zinc as sulfate (45), gluconate (12), acetate (6) and other compounds (8). Studies comparing zinc with iron versus zinc alone provided daily dose equivalents of 3--36 mg of iron. Outcomes were observed for about 26 weeks (median) after randomisation, with follow-up from 2--80 weeks.

Risk of bias {#s3c}
------------

Randomisation and allocation concealment were adequate in 34 and 32 studies; 46 and 48 studies were unclear ([figure 2](#BMJOPEN2013004647F2){ref-type="fig"}). For blinding of participants and personnel, 63 studies were at low risk of bias. For blinding of outcome assessment, 65 studies were at low risk of bias. For both types of blinding, 15 studies were unclear.

![Risk of bias summary.](bmjopen2013004647f02){#BMJOPEN2013004647F2}

For all analyses, we attempted to include all randomised study participants; 47 studies were at low risk of bias for incomplete data, 31 were unclear and 2 were at high risk. For selective reporting, 3 studies were at low risk of bias, 44 were at unclear risk and 32 were at high risk (see online supplementary appendix 5).

Bias may affect secondary outcomes in this review, but it does not appear to be important for the primary outcome. For example, mortality and other objective measures are not vulnerable to bias related to blinding, and many missing outcomes were biomarkers or growth related.

Effects of zinc supplementation {#s3d}
-------------------------------

In addition to outcomes included in the summary of findings table ([table 1](#BMJOPEN2013004647TB1){ref-type="table"}), we analysed results for hospitalisation; prevalence of morbidities; additional measures of growth; as well as biological indicators of zinc, haemoglobin, iron and copper status ([table 2](#BMJOPEN2013004647TB2){ref-type="table"}). Subgroup analyses compared the effects of zinc supplementation with and without iron coadministration ([table 3](#BMJOPEN2013004647TB3){ref-type="table"}, see online supplementary appendix 6).

###### 

Summary of findings

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                                  Illustrative comparative risks\* (95% CI)          Relative effect (95% CI)                                                          Number of participants (studies)   Quality of the evidence (GRADE)   
  ----------------------------------------- -------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------- --------------------------------- --------------
  All-cause mortality\                      Low                                                RR 0.95 (0.86 to 1.05)                                                            138 302 (13 studies)               ⊕⊕⊕⊕\                             
  Follow-up: 17--72 weeks                                                                                                                                                                                           High                              

  2400/1 000 000                            2280/1 000 000 (2064 to 2520)                                                                                                                                                                             

  High                                                                                                                                                                                                                                                

  34 900/1 000 000                          33 155/1 000 000 (30 014 to 36 645)                                                                                                                                                                       

  Mortality due to all-cause diarrhoea\     Low                                                RR 0.95 (0.69 to 1.31)                                                            132 321 (4 studies)                ⊕⊕⊕⊝\                             
  Follow-up: 52--69 weeks                                                                                                                                                                                           Moderate†                         

  800/1 000 000                             760/1 000 000 (552 to 1048)                                                                                                                                                                               

  High                                                                                                                                                                                                                                                

  3000/1 000 000                            2850/1 000 000 (2070 to 3930)                                                                                                                                                                             

  Mortality due to LRTI\                    Low                                                RR 0.86 (0.64 to 1.15)                                                            132 063 (3 studies)                ⊕⊕⊕⊝\                             
  Follow-up: 52--69 weeks                                                                                                                                                                                           Moderate†                         

  1200/1 000 000                            1032/1 000 000 (768 to 1380)                                                                                                                                                                              

  High                                                                                                                                                                                                                                                

  3000/1 000 000                            2580/1 000 000 (1920 to 3450)                                                                                                                                                                             

  Mortality due to malaria\                 Low                                                RR 0.90 (0.77 to 1.06)                                                            42 818 (2 studies)                 ⊕⊕⊕⊝\                             
  Follow-up: 46--69 weeks                                                                                                                                                                                           Moderate†                         

  7400/1 000 000                            6660/1 000 000 (5698 to 7844)                                                                                                                                                                             

  High                                                                                                                                                                                                                                                

  14 200/1 000 000                          12 780/1 000 000 (10 934 to 15 052)                                                                                                                                                                       

  Incidence of all-cause diarrhoea\         Low                                                RR 0.87 (0.85 to 0.89)                                                            15 042 (35 studies)                ⊕⊕⊝⊝\                             
  Follow-up: 12--72 weeks                                                                                                                                                                                           Low‡§                             

  20 000/1 000 000                          17 400/1 000 000 (17 000 to 17 800)                                                                                                                                                                       

  High                                                                                                                                                                                                                                                

  1 770 000/1 000 000                       1 539 900/1 000 000 (1 504 500 to 1 575 300)                                                                                                                                                              

  Incidence of LRTI\                        Low                                                                                                                                  RR 1.00 (0.94 to 1.07)             9610 (12 studies)                 ⊕⊕⊕⊕\
  Follow-up: 12--52 weeks                                                                                                                                                                                                                             High

  30 000/1 000 000                          30 000/1 000 000 (28 200 to 32 100)                                                                                                                                                                       

  High                                                                                                                                                                                                                                                

  370 000/1 000 000                         370 000/1 000 000 (347 800 to 395 900)                                                                                                                                                                    

  Incidence of malaria\                     Low                                                RR 1.05 (0.95 to 1.15)                                                            2407 (4 studies)                   ⊕⊕⊕⊝\                             
  Follow-up: 24--47 weeks                                                                                                                                                                                           Moderate¶                         

  140 000/1 000 000                         147 000/1 000 000 (133 000 to 161 000)                                                                                                                                                                    

  High                                                                                                                                                                                                                                                

  2 950 000/1 000 000                       3 097 500/1 000 000 (2 802 500 to 3 392 500)                                                                                                                                                              

  Height\                                   The mean height in the control groups was −1 HAZ   The mean height in the intervention groups was 0.1 HAZ better (0 to 0.2 better)   SMD 0.09 (0.06 to 0.13)            13 669 (51 studies)               ⊕⊕⊕⊝\
  Follow-up: 10--60 weeks                                                                                                                                                                                                                             Moderate\*\*

  Participants with one vomiting episode\   Low                                                RR 1.29 (1.14 to 1.46)                                                            35 192 (4 studies)                 ⊕⊕⊕⊕\                             
  Follow-up: 24--52 weeks                                                                                                                                                                                           High                              

  17 500/1 000 000                          22 575/1 000 000 (19 950 to 25 550)                                                                                                                                                                       

  High                                                                                                                                                                                                                                                

  300 600/1 000 000                         387 774/1 000 000 (342 684 to 438 876)                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GRADE working group grades of evidence.

High quality: further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: we are very uncertain about the estimate.

\*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

†Few deaths were observed overall.

‡I^2^=88%.

§Trim-and-fill analysis suggests that the effect may be overestimated due to publication bias.

¶I^2^=44%.

\*\*I^2^=86%.

LRTI, lower respiratory tract infection; SMD, standardised mean difference.

###### 

Zinc compared with no zinc (all outcomes)

  ----------------------------------------------------------------------------------------------------------------
  Outcomes                      Trials     People          ES (95% CI), fixed effects   Heterogeneity\
                                                                                        I^2^; χ^2^ (p Value)
  ----------------------------- ---------- --------------- ---------------------------- --------------------------
  *Zinc vs no zinc*                                                                     

  Mortality                                                                             

   All-cause                    13 (16%)   138 302 (67%)   Risk=0.95 (0.86 to 1.05)     0%; 10.57 (p=0.65)

   Due to diarrhoea             4 (5%)     132 321 (64%)   Risk=0.95 (0.69 to 1.31)     0%; 0.82 (p=0.84)

   Due to LRTI                  3 (4%)     132 063 (64%)   Risk=0.86 (0.64 to 1.15)     0%; 0.07 (p=0.96)

   Due to malaria               2 (3%)     42 818 (21%)    Risk=0.90 (0.77 to 1.06)     0%; 0.01 (p=0.94)

  Hospitalisation                                                                       

   All-cause                    7 (9%)     92 872 (45%)    Risk=1.04 (0.97 to 1.11)     44%; 14.41 (p=0.07)

   Due to diarrhoea             4 (5%)     74 039 (36%)    Risk=1.03 (0.87 to 1.22)     42%; 6.91 (p=0.14)

   Due to LRTI                  3 (4%)     74 743 (36%)    Risk=1.10 (0.93 to 1.30)     0%; 0.35 (p=0.95)

  Diarrhoea                                                                             

   Incidence (all-cause)        35 (44%)   15 042 (7%)     Risk=0.87 (0.85 to 0.89)     88%; 295.56 (p\<0.00001)

   Prevalence (all-cause)       13 (16%)   8519 (4%)       Rate=0.88 (0.86 to 0.90)     88%; 118.88 (p\<0.00001)

   Incidence (severe)           5 (6%)     4982 (2%)       Risk=0.89 (0.84 to 0.95)     56%; 13.54 (p=0.04)

   Incidence (persistent)       7 (9%)     6216 (3%)       Risk=0.73 (0.62 to 0.85)     61%; 20.47 (p=0.009)

   Prevalence (persistent)      1 (1%)     666 (0%)        Rate=0.70 (0.64 to 0.76)     91%; 11.76 (p=0.0006)

  LRTI                                                                                  

   Incidence                    12 (15%)   9610 (5%)       Risk=1.00 (0.94 to 1.07)     1%; 17.16 (p=0.44)

   Prevalence                   3 (4%)     1955 (1%)       Rate=1.20 (1.10 to 1.30)     97%; 89.87 (p\<0.00001)

  Malaria                                                                               

   Incidence                    4 (5%)     2407 (1%)       Risk=1.05 (0.95 to 1.15)     0%; 2.04 (p=0.84)

   Prevalence                   1 (1%)     661 (0%)        Rate=0.88 (0.47 to 1.64)     Not applicable

  Growth                                                                                

   Height                       51 (64%)   13 669 (7%)     SMD=0.09 (0.06 to 0.13)      86%; 407.92 (p\<0.00001)

   Weight                       44 (55%)   12 305 (6%)     SMD=0.10 (0.07 to 0.14)      76%; 216.64 (p\<0.00001)

   Weight-to-height ratio       24 (30%)   7901 (4%)       SMD=0.05 (0.01 to 0.10)      20%; 34.96 (p=0.17)

   Prevalence of stunting       6 (8%)     3838 (2%)       Risk=0. 94 (0.86 to 1.02)    59%; 19.43 (p=0.01)

  AEs                                                                                   

   Participants with one AE     2 (3%)     850 (0%)        SMD=1.13 (1.00 to 1.27)      0%; 0.49 (p=0.78)

   Study withdrawal             6 (8%)     4263 (2%)       Risk=1.75 (0.93 to 3.32)     21%; 5.07 (p=0.28)

   Vomiting (incidence)         5 (6%)     4095 (2%)       Risk=1.68 (1.61 to 1.75)     85%; 34.28 (p\<0.00001)

   Vomiting (prevalence)        4 (5%)     35 192 (17%)    Rate=1.29 (1.14 to 1.46)     37%; 6.31 (p=0.18)

  Biological indicators                                                                 

   Zn concentration             46 (58%)   9810 (5%)       SMD=0.62 (0.58 to 0.67)      91%; 582.45 (p\<0.00001)

   Zn deficiency (prevalence)   15 (19%)   5434 (3%)       Risk=0.49 (0.45 to 0.53)     86%; 144.77 (p\<0.00001)

   Haemoglobin concentration    27 (34%)   6024 (3%)       SMD=−0.05 (−0.10 to 0.00)    45%; 63.96 (p=0.002)

   Anaemia (prevalence)         13 (16%)   4287 (2%)       Risk=1.00 (0.95 to 1.06)     37%; 28.52 (p=0.05)

   Fe concentration             19 (24%)   4474 (2%)       SMD=0.07 (0.00 to 0.13)      95%; 480.50 (p\<0.00001)

   Fe deficiency (prevalence)   10 (13%)   3149 (2%)       Risk=0.99 (0.89 to 1.10)     15%; 16.44 (p=0.29)

   Cu concentration             11 (14%)   3071 (1%)       SMD=−0.22 (−0.29 to 0.14)    68%; 37.47 (p=0.0002)

   Cu deficiency (prevalence)   3 (4%)     1337 (1%)       Risk=2.64 (1.28 to 5.42)     59%; 4.94 (p=0.08)
  ----------------------------------------------------------------------------------------------------------------

AE, adverse event; ES, effect size; LRTI, lower respiratory tract infection; SMD, standardised mean difference.

###### 

Subgroup analyses

  Subgroup                                                       Trials   People    Risk ratio (95% CI), fixed   I^2^; χ^2^ (p Value)
  -------------------------------------------------------------- -------- --------- ---------------------------- --------------------------
   Iron cosupplementation (I^2^=23%; χ^2^=1.30, p=0.25)                                                          
  *  *With iron                                                  4        99 242    0.99 (0.86 to 1.15)          0%; 0.76 (p=0.86)
  *  *Without iron                                               11       64 985    0.89 (0.79 to 1.00)          0%; 9.99 (p=0.44)
  * *Age (I^2^=59.8%; χ^2^=2.48, p=0.11)                                                                         
  *  *6 months to 1 year                                         6        29 879    1.06 (0.88 to 1.27)          0%; 2.56 (p=0.77)
  *  *1--5 years                                                 8        125 903   0.89 (0.80 to 0.99)          12%; 10.28 (p=0.33)
  * *Dose, mg (I^2^=0%; χ^2^=2.64, p=0.45)                                                                       
  *  *0--5                                                       2        717       0.72 (0.08 to 6.47)          29%; 1.41 (p=0.23)
  *  *5--10                                                      1        274       3.04 (0.32 to 28.90)         Not applicable
  *  *10--15                                                     11       152 062   0.93 (0.84 to 1.02)          0%; 8.16 (p=0.61)
  *  *20 or more                                                 1        2464      0.14 (0.01 to 2.78)          Not applicable
  * *Duration, months (I^2^=0%; χ^2^=1.20, p=0.55)                                                               
  *  *0--6                                                       2        2817      0.59 (0.07 to 5.15)          47%; 1.88. (p=0.17.)
  *  *6--12                                                      7        3898      0.68 (0.37 to 1.25)          4%; 6.23 (p=0.40)
  *  *12 or more                                                 6        148 802   0.93 (0.85 to 1.03)          0%; 2.91 (p=0.71)
  * *Formulation (I^2^=0%; χ^2^=0.54, p=0.91)                                                                    
  *  *Solution                                                   5        3639      0.99 (0.25 to 3.91)          15%; 4.68 (p=0.32)
  *  *Pill/tablet                                                8        149 854   0.93 (0.85 to 1.02)          0%; 6.99 (p=0.43)
  *  *Capsule                                                    1        306       0.51 (0.05 to 5.60)          Not applicable
  *  *Powder                                                     1        1718      0.71 (0.27 to 1.86)          Not applicable
  Incidence of diarrhoea                                         35       15 042    0.87 (0.85 to 0.89)          88%; 295.56 (p\<0.00001)
  * *Iron cosupplementation (I^2^=99%; χ^2^=65.11, p\<0.00001)                                                   
  *  *With iron                                                  10       4299      1.00 (0.96 to 1.05)          76%; 37.33 (p\<0.00001)
  *  *Without iron                                               22       11 344    0.82 (0.80 to 0.84)          87%; 196.27 (p\<0.00001)
  * *Age (I^2^=0%; χ^2^=0.32, p=0.85)                                                                            
  *  *6 months to 1 year                                         10       5576      0.88 (0.85 to 0.90)          95%; 252.46 (p\<0.00001)
  *  *1--5 years                                                 15       8370      0.87 (0.84 to 0.90)          43%; 31.48 (p=0.03)
  *  *5--13 years                                                1        842       0.90 (0.81 to 0.98)          Not applicable
  * *Dose, mg (I^2^=98%; χ^2^=195.69, p\<0.00001)                                                                
  *  *0--5                                                       4        1784      0.95 (0.89 to 1.01)          73%; 22.46 (p=0.001)
  *  *5--10                                                      6        2630      0.73 (0.64 to 0.83)          67%; 15.32 (p=0.009)
  *  *10--15                                                     11       5452      0.96 (0.92 to 0.99)          69%; 38.39 (p=0.0001)
  *  *15--20                                                     2        477       0.61 (0.58 to 0.65)          0%; 0.21 (p\<0.00001)
  *  *20 or more                                                 6        4931      0.90 (0.87 to 0.94)          75%; 28.17 (p\<0.00001)
  * *Duration, months (I^2^=0%; χ^2^=1.15, p=0.56)                                                               
  *  *0--6                                                       7        4190      0.89 (0.85 to 0.93)          57%; 16.42 (p=0.02)
  *  *6--12                                                      14       8971      0.86 (0.84 to 0.89)          93%; 250.92 (p\<0.00001)
  *  *12 or more                                                 5        1881      0.88 (0.82 to 0.95)          73%; 29.82 (p=0.0002)
  * *Formulation (I^2^=94%; χ^2^=51.34, p\<0.00001)                                                              
  *  *Solution                                                   19       10 768    0.84 (0.82 to 0.86)          90%; 236.48 (p\<0.00001)
  *  *Pill/tablet                                                3        1696      0.90 (0.81 to 0.99)          5%; 3.15 (p=0.37)
  *  *Capsule                                                    1        612       0.78 (0.60 to 1.01)          Not applicable
  *  *Powder                                                     2        1861      1.04 (0.98 to 1.09)          0%; 0.65 (p=0.42)

Fourteen studies including 138 302 participants were analysed for all-cause mortality, though other studies included no deaths in either group ([figure 3](#BMJOPEN2013004647F3){ref-type="fig"}), and there was high quality evidence of a small effect (risk ratio 0.95 (0.86 to 1.05)). There were similar effects for mortality due to diarrhoea (RR 0.95 (0.69 to 1.31)), mortality due to lower respiratory tract infection (LRTI; RR 0.86 (0.64 to 1.15)) and mortality due to malaria (RR 0.90 (0.77 to 1.06)), and the evidence for these outcomes was moderate quality.

![All-cause mortality by age.](bmjopen2013004647f03){#BMJOPEN2013004647F3}

In 25 studies including 15 042 participants, there was low quality evidence of a 13% reduction in incidence of all-cause diarrhoea ([figure 4](#BMJOPEN2013004647F4){ref-type="fig"}; RR 0.87 (0.85 to 0.89)). Other measures of diarrhoea were consistent with no difference or with a small reduction in morbidity, including prevalence of all-cause diarrhoea, hospitalisation due to all-cause diarrhoea, incidence of severe diarrhoea, prevalence of severe diarrhoea, incidence of persistent diarrhoea and prevalence of persistent diarrhoea.

![Incidence of all-cause diarrhoea with and without iron cosupplementation.](bmjopen2013004647f04){#BMJOPEN2013004647F4}

In 12 trials (9610 participants), there was high-quality evidence of no effect on LRTI incidence (see online supplementary appendix 7; RR 1.00 (0.94 to 1.07)). One trial reported no LRTI in either group.[@R20] Results for prevalence were consistent with no difference in respiratory morbidity.

Four trials (2407 participants) found moderate quality evidence that would be consistent with no effect or a harmful effect on malaria incidence (RR 1.04 (0.94, 1.14)). One study reported no significant effect on malaria prevalence.

Fifty studies reported height for 13 669 participants ([figure 5](#BMJOPEN2013004647F5){ref-type="fig"}). There was moderate quality evidence of a very small but statistically significant increase in linear growth (SMD 0.09 (0.06 to 0.13)). Results for weight, weight-to-height ratio and prevalence of stunting were consistent with no difference or a small effect on growth.

![Height.](bmjopen2013004647f05){#BMJOPEN2013004647F5}

Forty-six studies reported serum zinc for 9810 participants. There was evidence of a medium effect (SMD 0.62 (0.58 to 0.67)) on zinc concentration. Results consistently favoured zinc rather than no-intervention, but they were extremely inconsistent in magnitude, possibly due to differences in participants and settings (χ^2^=582.45, df=47 (p\<0.00001); I^2^=91%). Eleven studies reported serum copper for 3071 participants (1% of participants in this review). There was very low-quality evidence of a small reduction in copper (SMD −0.22 (−0.29 to 0.14)); as above, the results were inconsistent (χ^2^=37.47, df=10 (p\<0.0002); I^2^=68%). There was no evidence of an effect on haemoglobin, prevalence of anaemia or iron status.

In five trials (35 192participants), there was high-quality evidence of increased vomiting (RR 1.29 (1.14 to 1.46)). Two trials reported no adverse events in either group (ie, supplemented or non-supplemented).[@R21] [@R22] Results for study withdrawal, participants with one or more side effects and number of vomiting episodes indicate some short-term side effects; there was no evidence of serious adverse events.

Effects of zinc plus iron compared with zinc alone {#s3e}
--------------------------------------------------

Effects on mortality were not significantly different between subgroups with and without iron (χ^2^=1.30, p=0.25); however, there was no mortality effect in groups receiving iron (RR 0.99 (0.86 to 1.15)) while the effect for groups that did not receive iron was nearly significant (RR 0.89 (0.79 to 1.00)). Effects on the incidence of diarrhoea differed between groups ([figure 4](#BMJOPEN2013004647F4){ref-type="fig"}; χ^2^=65.11, p\<0.00001), with no benefit for the group that received iron (RR 1.00 (0.96 to 1.05)) and a significant benefit for the group that did not receive iron (RR 0.82 (0.80 to 0.84)). There were significant effects with and without iron cosupplementation on zinc status; these were greater in studies without iron for serum zinc (χ^2^=27.07, p\<0.00001) and prevalence of zinc deficiency (χ^2^=34.27, p\<0.00001). There were also differences between these groups of studies for serum ferritin and serum copper; zinc had no effect in studies with iron cointervention, but zinc without iron cointervention reduced ferritin and copper. Overall effects on growth were small; there was a significant difference between subgroups for height but not weight, and the difference for weight-to-height ratio favoured the group that received iron (ie, the opposite of the other results). There were no significant effects in either subgroup for LRTIs, serum haemoglobin, prevalence of anaemia or prevalence of iron deficiency.

Several trials compared zinc coadministered with iron versus zinc given alone (see online supplementary appendix 6). One trial reported no significant difference in all-cause mortality (323 participants; RR 0.33 (0.01 to 8.39)). In five trials (1530 participants), effects on incidence of all-cause diarrhoea favoured zinc alone (RR 1.10 (1.03 to 1.18)). In one trial (399 participants), effects on prevalence of all-cause diarrhoea favoured zinc with iron, but this was not significant (RR 0.90 (0.79 to 1.06)). Five trials (1329 participants) reported no difference in height (SMD 0.06 (−0.04 to 0.16)). Similarly, there was low-quality evidence and mixed results for other outcomes ([table 4](#BMJOPEN2013004647TB4){ref-type="table"}).

###### 

Zinc with iron compared with zinc alone (all outcomes)

  -------------------------------------------------------------------------------------------------------------------
  Outcomes                            Trials     People       ES (95% CI), fixed effects   Heterogeneity\
                                                                                           I^2^; χ^2^ (p Value)
  ----------------------------------- ---------- ------------ ---------------------------- --------------------------
  All-cause mortality                 1 (13%)    323 (17%)    Risk=0.33 (0.01 to 8.31)     Not applicable

  Hospitalisation                                                                          

  * *All-cause                        1 (13%)    399 (21%)    Risk=0.92 (0.45 to 1.89)     Not applicable

  * *Due to diarrhoea                 1 (13%)    399 (21%)    Risk=0.99 (0.25 to 3.88)     Not applicable

  Diarrhoea                                                                                

  * *Incidence (all-cause)            5 (63%)    1530 (81%)   Risk=1.10 (1.03 to 1.18)     76%; 16.92 (p=0.002)

  * *Prevalence (all-cause)           1 (13%)    399 (21%)    Rate=0.90 (0.79 to 1.06)     Not applicable

  * *Incidence (severe)               1 (13%)    323 (17%)    Rate=0.78 (0.59 to 1.04)     Not applicable

  Lower respiratory tract infection                                                        

  * *Incidence                        3 (38%)    1065 (56%)   Risk=0.93 (0.83 to 1.04)     21%; 2.52 (p=0.28)

  Malaria                                                                                  

  * *Incidence                        1 (13%)    410 (22%)    Rate=0.86 (0.59 to 1.24)     Not applicable

  Growth                                                                                   

  * *Height                           5 (63%)    1517 (80%)   SMD=0.06 (−0.04 to 0.16)     0%; 3.54 (p=0.47)

  * *Weight                           4 (50%)    910 (48%)    SMD=0.12 (−0.01 to 0.25)     0%; 2.29 (p=0.51)

  * *Weight-to-height ratio           4 (50%)    514 (27%)    SMD=−0.06 (−0.07 to 0.19)    0%; 1.36 (p=0.71)

  * *Prevalence of stunting           2 (25%)    462 (24%)    Risk=0.92 (0.85 to 0.99)     45%; 1.82 (p=0.18)

  Adverse events                                                                           

  * *Study withdrawal                 2 (25%)    557 (29%)    Risk=1.41 (0.91 to 2.18)     0%; 0.08 (p=0.78)

  Biological indicators                                                                    

  * *Zn concentration                 8 (100%)   1337 (70%)   SMD=0.16 (0.05 to 0.27)      61%; 17.84 (p=0.01)

  * *Zn deficiency (prevalence)       3 (38%)    350 (18%)    Risk=1.42 (0.75 to 2.68)     5%; 2.10 (p=0.35)

  * *Haemoglobin concentration        8 (100%)   1341 (71%)   SMD=−0.23 (−0.34 to −0.12)   79%; 33.53 (p\<0.0001)

  * *Anaemia (prevalence)             3 (38%)    482 (25%)    Risk=0.78 (0.67 to 0.92)     0%; 1.25 (p=0.54)

  * *Fe concentration                 6 (75%)    945 (50%)    SMD=−1.79 (−1.99 to −1.56)   99%; 927.92 (p\<0.00001)

  * *Fe deficiency (prevalence)       2 (25%)    248 (13%)    Risk=0.12 (0.04 to 0.32)     87%; 8.00 (p=0.005)

  * *Cu concentration                 2 (25%)    353 (19%)    SMD=−0.06 (−0.27 to 0.15)    0%; 0.11 (p=0.74)
  -------------------------------------------------------------------------------------------------------------------

Effects favour intervention (ie, zinc rather than iron; zinc plus iron rather than zinc alone) when the relative risk is reduced (RR\<1) or the standardised difference is positive (SMD\>0).

ES, effect size; Rate, rate ratio; Risk, risk ratio; SMD, standardised mean difference.

Additional subgroup analyses {#s3f}
----------------------------

Studies in high-income countries did not evaluate most outcomes, so we were unable to explore differences in effect by national income. Effects on weight and weight-to-height ratio were not statistically different, and there was no evidence of consistent differences in biological outcomes (see online supplementary appendix 6).

Most studies included stunted and non-stunted children, and it was not possible to compare effects between studies for most outcomes. Differences between groups were not significant for growth, but these would be consistent with larger effects in studies of stunted children.

Age was not significantly associated with effects on mortality or incidence diarrhoea, but results would be consistent with greater benefits in children over 1 year of age ([figure 3](#BMJOPEN2013004647F3){ref-type="fig"}). Effects on weight were greatest in studies of older children, and there was a similar pattern for height, though the largest study of children over 5 years of age included only 804 participants. The effect of supplementation on zinc deficiency was greater in studies of older children, as was the negative effect on copper. There was no evidence of consistent differences in other biological outcomes.

Dose was not significantly associated with effects on mortality, incidence of LRTI, haemoglobin or weight-to-height ratio. The pattern of results was inconsistent for incidence and prevalence of diarrhoea, height, weight and plasma ferritin (see online supplementary appendix 6). Subgroups were significantly different for serum zinc, prevalence of zinc deficiency, prevalence of iron deficiency and plasma copper; only these results are consistent with a dose--response relationship.

Duration of supplementation was not significantly associated with effects on mortality, incidence of diarrhoea, incidence of LRTI, weight-to-height ratio or prevalence of iron deficiency (see online supplementary appendix 6). There was a significant difference for prevalence of diarrhoea, but the magnitude of this difference may not be important. Studies of longer supplementation were associated with greater effects on height; the pattern of results was not consistent for weight. By contrast, the largest benefits for biological markers (serum zinc and prevalence of zinc deficiency) were reported in the shortest studies.

Formulation was associated with differences among subgroups, though few studies included capsules or powder. When comparing solution and tablets, differences were not significant for mortality, incidence and prevalence of diarrhoea; incidence of LRTI; blood haemoglobin; prevalence of anaemia or prevalence of iron deficiency. There were significant differences in the effects of serum ferritin and serum copper, but only three studies of each outcome used tablets, and they were highly heterogeneous. The effects on height, weight and serum zinc were greater in studies using solution compared with tablet, but all effects were small (see online supplementary appendix 6).

Reporting bias {#s3g}
--------------

For outcomes included in the summary of findings table with 10 or more studies, we also conducted a trim-and-fill analysis to investigate reporting bias (see online supplementary appendix 8).[@R23] There was some evidence of small study bias---studies were trimmed for all-cause mortality (1 trimmed) and incidence of all-cause diarrhoea (13 trimmed; [figure 6](#BMJOPEN2013004647F6){ref-type="fig"}). None were trimmed for incidence of LRTI; nor were any trimmed for height. The adjusted effect for mortality was not importantly different from the observed effect, but the observed effect for diarrhoea (RR 0.87 (0.85 to 0.89)) was larger than the adjusted value (RR 0.95 (0.93 to 0.97)).

![Incidence of diarrhoea funnel plot (trim-and-fill analysis).](bmjopen2013004647f06){#BMJOPEN2013004647F6}

Discussion {#s4}
==========

Consistent with previous reviews, this review finds high-quality evidence from several large, well-conducted trials.[@R5] [@R7] [@R10] We believe that these results suggest zinc supplementation is probably associated with a small reduction in all-cause mortality for children at risk of deficiency. In interpreting these results, we considered that the results of this meta-analysis are drawn from 13 trials including almost 140 000 participants. The results of those studies are statistically consistent, the overall CIs are relatively small and the balance of probability favours zinc supplementation rather than placebo. Small reductions in cause-specific mortality were consistent with effects on illness and cause-specific mortality, and the results were biologically plausible. Benefits in any specific area may be related to the level of deficiency; countries with very high levels of deficiency could expect the largest reductions in mortality as a result of supplementation.[@R24] This review also suggests that benefits may not be restricted to young children; there is some evidence of benefits on secondary outcomes in trials including children over 5 years of age, but there is a lack of evidence about the effects on mortality in this group.

Results for secondary outcomes suggest modest benefits. The main results for diarrhoea morbidity were consistent with previous reviews,[@R4] [@R5] [@R7] [@R10] but an asymmetrical funnel plot was indicative of small-study bias. After adjustment, the effect for diarrhoea was halved, and the reduced estimate was consistent with other critical outcomes in this review. Previous reviews have suggested beneficial effects on respiratory infections[@R4] [@R5] [@R9] and malaria,[@R10] which this review does not confirm, and also reported variable effects on growth[@R5] [@R6] [@R8]; this review suggests that preventive zinc supplementation alone is unlikely to have large effects on linear growth and morbidity. Supplementation is associated with increased risk of vomiting, but there is no evidence of lasting adverse effects.

Critical outcomes included data for 2407--138 302 participants, so further placebo-controlled trials of preventive zinc supplementation for young children may not be necessary. However, subgroup analyses did not identify an optimal supplementation strategy (ie, dose, formulation and frequency), and large trials comparing active interventions could inform clinical guidelines. Subgroup analyses identify some sources of observed heterogeneity; however, subgroups that were statistically different included a large amount of residual heterogeneity, which is reflected in our judgements about the quality of the evidence ([table 1](#BMJOPEN2013004647TB1){ref-type="table"}). Analyses of group-level data are of limited value for identifying moderators, particularly in analyses dominated by a few large studies. Further analyses of individual patient data would be more conclusive.

Effects on biological indicators were inconsistent across studies, but large effects on these measures were not always reflected in clinical outcomes. Supplementation may increase serum zinc, but the magnitude of the effect appears to differ across populations and interventions. Effects on other micronutrients, including iron and copper, are uncertain. Researchers have suggested that iron supplementation may interfere with the absorption of zinc and, conversely, that zinc may interfere with iron and copper absorption[@R25] [@R26]; however, the relationships between these biomarkers and clinical outcomes (ie, mortality and morbidities) have not been established.

Subgroup analyses comparing zinc with and without iron did not resolve uncertainty about the effect of cosupplementation. Only four studies with iron cosupplementation reported mortality outcomes, and evidence of outcome reporting bias for diarrhoea incidence leads to cautious interpretation of differences in this outcome. There was no evidence that larger doses or increased duration was associated with increased iron deficiency, but these comparisons are observational and could be affected by uncontrolled covariates.

Direct comparisons within trials provide the only experimental evidence about the effects of cosupplementation with iron. For rare events like mortality, effects of zinc and iron can only be detected in large studies, so studies of interaction effects will need to be very large to detect real differences. Future studies are needed to identify the main effects and to explore how administration (ie, separate or combined) affects uptake and costs.

Dietary intake and supplementation have reduced micronutrient deficiencies in Asia, but micronutrient deficiencies remain common.[@R3] [@R27] The prevalence of micronutrient deficiencies is declining in Africa, but the absolute number of deficient children is increasing.[@R3] This review suggests that the overall benefits of preventive zinc supplementation outweigh potential harms in areas with a high risk of zinc deficiency. Further research is needed to determine if these benefits extend to children over 5 years of age. Current estimates suggest that delivering 10 evidence-based nutrition-specific interventions, including preventive zinc supplements, could reduce global mortality in children under 5 years of age by 15%.[@R28] To that end, research is needed to identify the most effective strategies for delivering zinc supplements to populations in need.[@R29]
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